United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a reiterated with a price target of $0.00 to $300.00. The current price United Therapeutics (UTHR) is trading at is $243.75, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/23/2023 | 23.08% | HC Wainwright & Co. | → $300 | Reiterates | → Buy |
| 01/11/2023 | 23.08% | Argus Research | $250 → $300 | Maintains | Buy |
| 12/06/2022 | 35.38% | Morgan Stanley | $322 → $330 | Maintains | Overweight |
| 12/06/2022 | 31.28% | UBS | → $320 | Initiates Coverage On | → Buy |
| 12/05/2022 | -5.64% | Goldman Sachs | → $230 | Initiates Coverage On | → Sell |
| 11/03/2022 | 8.72% | JP Morgan | $240 → $265 | Maintains | Overweight |
| 11/03/2022 | 32.1% | Morgan Stanley | $288 → $322 | Maintains | Overweight |
| 11/03/2022 | 53.85% | Oppenheimer | $325 → $375 | Maintains | Outperform |
| 11/03/2022 | 23.08% | HC Wainwright & Co. | $255 → $300 | Maintains | Buy |
| 10/11/2022 | 18.15% | Morgan Stanley | → $288 | Initiates Coverage On | → Overweight |
| 05/24/2022 | -2.36% | JP Morgan | $225 → $238 | Maintains | Overweight |
| 05/24/2022 | 0.51% | Jefferies | $223 → $245 | Maintains | Buy |
| 05/24/2022 | 7.9% | Wedbush | $236 → $263 | Maintains | Outperform |
| 05/24/2022 | 1.33% | Credit Suisse | $219 → $247 | Maintains | Outperform |
| 05/24/2022 | 4.62% | HC Wainwright & Co. | $248 → $255 | Maintains | Buy |
| 04/19/2022 | -8.51% | JP Morgan | $230 → $223 | Maintains | Overweight |
| 02/28/2022 | -3.18% | Wedbush | $276 → $236 | Maintains | Outperform |
| 02/25/2022 | -16.72% | Ladenburg Thalmann | $231 → $203 | Maintains | Buy |
| 02/11/2022 | — | BTIG | Initiates Coverage On | → Neutral | |
| 07/14/2021 | -15.9% | Argus Research | → $205 | Upgrades | Hold → Buy |
| 05/06/2021 | 1.74% | HC Wainwright & Co. | $195 → $248 | Maintains | Buy |
| 04/08/2021 | -13.03% | JP Morgan | $185 → $212 | Maintains | Overweight |
| 02/22/2021 | -19.59% | Credit Suisse | $169 → $196 | Maintains | Outperform |
| 02/16/2021 | 12.82% | Oppenheimer | $200 → $275 | Maintains | Outperform |
| 02/01/2021 | -20% | HC Wainwright & Co. | $125 → $195 | Upgrades | Neutral → Buy |
| 07/30/2020 | -32.31% | Oppenheimer | $155 → $165 | Maintains | Outperform |
| 07/30/2020 | 0.1% | Wedbush | $243 → $244 | Maintains | Outperform |
| 06/25/2020 | -40.51% | Credit Suisse | $129 → $145 | Maintains | Outperform |
| 06/25/2020 | -48.72% | HC Wainwright & Co. | $85 → $125 | Maintains | Neutral |
| 03/10/2020 | -49.54% | Jefferies | $115 → $123 | Upgrades | Hold → Buy |
| 02/27/2020 | -40.51% | Cowen & Co. | $119 → $145 | Upgrades | Market Perform → Outperform |
| 02/13/2020 | -50.36% | Credit Suisse | $113 → $121 | Maintains | Outperform |
| 01/31/2020 | -50.77% | JP Morgan | $116 → $120 | Upgrades | Neutral → Overweight |
| 08/01/2019 | -56.51% | Ladenburg Thalmann | $103 → $106 | Upgrades | Neutral → Buy |
| 08/01/2019 | -63.08% | Jefferies | → $90 | Upgrades | Underperform → Hold |
| 07/01/2019 | — | Credit Suisse | Upgrades | Neutral → Outperform | |
| 05/17/2019 | -61.44% | UBS | $115 → $94 | Upgrades | Sell → Neutral |
| 05/09/2019 | — | Credit Suisse | Upgrades | Underperform → Neutral | |
| 05/02/2019 | 12% | Wedbush | $269 → $273 | Maintains | Outperform |
| 03/01/2019 | -61.03% | Barclays | $100 → $95 | Maintains | Underweight |
| 11/19/2018 | -56.92% | Credit Suisse | $103 → $105 | Maintains | Underperform |
| 11/02/2018 | -48.31% | JP Morgan | $118 → $126 | Maintains | Neutral |
| 11/01/2018 | -57.74% | Credit Suisse | $106 → $103 | Maintains | Underperform |
| 10/12/2018 | — | Standpoint Research | Upgrades | Hold → Buy | |
| 08/02/2018 | 3.79% | Wedbush | $234 → $253 | Maintains | Outperform |
| 07/10/2018 | -56.1% | Credit Suisse | $104 → $107 | Maintains | Neutral |
| 05/03/2018 | -61.03% | Barclays | $105 → $95 | Maintains | Underweight |
| 05/03/2018 | -57.33% | Credit Suisse | $108 → $104 | Maintains | Neutral |
| 04/03/2018 | — | Credit Suisse | Upgrades | Underperform → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/23/2023 | 23.08% | HC Wainwright公司 | → $300 | 重申 | →購買 |
| 01/11/2023 | 23.08% | Argus研究 | $250 → $300 | 維護 | 買 |
| 12/06/2022 | 35.38% | 摩根士丹利 | $322 → $330 | 維護 | 超重 |
| 12/06/2022 | 31.28% | 瑞銀集團 | → $320 | 開始承保 | →購買 |
| 12/05/2022 | -5.64% | 高盛 | → $230 | 開始承保 | →銷售 |
| 11/03/2022 | 8.72% | 摩根大通 | $240 → $265 | 維護 | 超重 |
| 11/03/2022 | 32.1% | 摩根士丹利 | $288 → $322 | 維護 | 超重 |
| 11/03/2022 | 53.85% | 奧本海默 | $325 → $375 | 維護 | 跑贏大盤 |
| 11/03/2022 | 23.08% | HC Wainwright公司 | $255 → $300 | 維護 | 買 |
| 10/11/2022 | 18.15% | 摩根士丹利 | → $288 | 開始承保 | →超重 |
| 05/24/2022 | -2.36% | 摩根大通 | $225 → $238 | 維護 | 超重 |
| 05/24/2022 | 0.51% | 傑富瑞 | $223 → $245 | 維護 | 買 |
| 05/24/2022 | 7.9% | 韋德布什 | $236 → $263 | 維護 | 跑贏大盤 |
| 05/24/2022 | 1.33% | 瑞士信貸 | $219 → $247 | 維護 | 跑贏大盤 |
| 05/24/2022 | 4.62% | HC Wainwright公司 | $248 → $255 | 維護 | 買 |
| 04/19/2022 | -8.51% | 摩根大通 | $230 → $223 | 維護 | 超重 |
| 02/28/2022 | -3.18% | 韋德布什 | $276 → $236 | 維護 | 跑贏大盤 |
| 02/25/2022 | -16.72% | 拉登堡·塔爾曼 | $231 → $203 | 維護 | 買 |
| 02/11/2022 | — | BTIG | 開始承保 | →中性 | |
| 07/14/2021 | -15.9% | Argus研究 | → $205 | 升級 | 持有→購買 |
| 05/06/2021 | 1.74% | HC Wainwright公司 | $195 → $248 | 維護 | 買 |
| 04/08/2021 | -13.03% | 摩根大通 | $185 → $212 | 維護 | 超重 |
| 02/22/2021 | -19.59% | 瑞士信貸 | $169 → $196 | 維護 | 跑贏大盤 |
| 02/16/2021 | 12.82% | 奧本海默 | $200 → $275 | 維護 | 跑贏大盤 |
| 02/01/2021 | -20% | HC Wainwright公司 | $125 → $195 | 升級 | 中性→購買 |
| 07/30/2020 | -32.31% | 奧本海默 | $155 → $165 | 維護 | 跑贏大盤 |
| 07/30/2020 | 0.1% | 韋德布什 | $243 → $244 | 維護 | 跑贏大盤 |
| 06/25/2020 | -40.51% | 瑞士信貸 | $129 → $145 | 維護 | 跑贏大盤 |
| 06/25/2020 | -48.72% | HC Wainwright公司 | $85 → $125 | 維護 | 中性 |
| 03/10/2020 | -49.54% | 傑富瑞 | $115 → $123 | 升級 | 持有→購買 |
| 02/27/2020 | -40.51% | 考恩公司 | $119 → $145 | 升級 | 市場表現優於→ |
| 02/13/2020 | -50.36% | 瑞士信貸 | $113 → $121 | 維護 | 跑贏大盤 |
| 01/31/2020 | -50.77% | 摩根大通 | $116 → $120 | 升級 | 中性→超重 |
| 08/01/2019 | -56.51% | 拉登堡·塔爾曼 | $103 → $106 | 升級 | 中性→購買 |
| 08/01/2019 | -63.08% | 傑富瑞 | → $90 | 升級 | 表現不佳的→保持 |
| 07/01/2019 | — | 瑞士信貸 | 升級 | 中性→表現優異 | |
| 05/17/2019 | -61.44% | 瑞銀集團 | $115 → $94 | 升級 | 賣出→中性 |
| 05/09/2019 | — | 瑞士信貸 | 升級 | 表現不佳的→中性 | |
| 05/02/2019 | 12% | 韋德布什 | $269 → $273 | 維護 | 跑贏大盤 |
| 03/01/2019 | -61.03% | 巴克萊 | $100 → $95 | 維護 | 體重不足 |
| 11/19/2018 | -56.92% | 瑞士信貸 | $103 → $105 | 維護 | 表現不佳 |
| 11/02/2018 | -48.31% | 摩根大通 | $118 → $126 | 維護 | 中性 |
| 11/01/2018 | -57.74% | 瑞士信貸 | $106 → $103 | 維護 | 表現不佳 |
| 10/12/2018 | — | 立場研究 | 升級 | 持有→購買 | |
| 08/02/2018 | 3.79% | 韋德布什 | $234 → $253 | 維護 | 跑贏大盤 |
| 07/10/2018 | -56.1% | 瑞士信貸 | $104 → $107 | 維護 | 中性 |
| 05/03/2018 | -61.03% | 巴克萊 | $105 → $95 | 維護 | 體重不足 |
| 05/03/2018 | -57.33% | 瑞士信貸 | $108 → $104 | 維護 | 中性 |
| 04/03/2018 | — | 瑞士信貸 | 升級 | 表現不佳的→中性 |
What is the target price for United Therapeutics (UTHR)?
聯合治療公司(UTHR)的目標價格是多少？
The latest price target for United Therapeutics (NASDAQ: UTHR) was reported by HC Wainwright & Co. on February 23, 2023. The analyst firm set a price target for $300.00 expecting UTHR to rise to within 12 months (a possible 23.08% upside). 18 analyst firms have reported ratings in the last year.
聯合治療公司(納斯達克代碼：UTHR)的最新目標價是由HC Wainwright&Co.於2023年2月23日報道的。這家分析公司將目標價定為300.00美元，預計UTHR將在12個月內升至(可能上漲23.08%)。去年有18家分析公司公佈了評級。
What is the most recent analyst rating for United Therapeutics (UTHR)?
聯合治療公司(UTHR)的最新分析師評級是多少？
The latest analyst rating for United Therapeutics (NASDAQ: UTHR) was provided by HC Wainwright & Co., and United Therapeutics reiterated their buy rating.
聯合治療公司(納斯達克代碼：UTHR)的最新分析師評級由HC Wainwright&Co.提供，聯合治療公司重申了其買入評級。
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
聯合治療公司(UTHR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on February 23, 2023 so you should expect the next rating to be made available sometime around February 23, 2024.
分析師們在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與聯合治療公司的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。聯合治療公司的上一次評級是在2023年2月23日提交的，所以你應該預計下一次評級將在2024年2月23日左右的某個時候提供。
Is the Analyst Rating United Therapeutics (UTHR) correct?
分析師對聯合治療公司(UTHR)的評級正確嗎？
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a reiterated with a price target of $0.00 to $300.00. The current price United Therapeutics (UTHR) is trading at is $243.75, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的聯合治療公司(UTHR)評級被重申，目標價在0.00美元至300.00美元之間。聯合治療公司目前的交易價格為243.75美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。